Biomarkers, Diagnostics and Precision Medicine in the Drug Industry

Critical Challenges, Limitations and Roadmaps for the Best Practices

Abdel Halim
Elsevier S&T
294 pages
ISBN-13: 978-0128161210
June 2019

The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies.